NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$3.78
+0.15 (+4.13%)
Open$3.66
Previous Close$3.63
Day High$3.80
Day Low$3.66
52W High$8.49
52W Low$2.57
Volume—
Avg Volume50.7K
Market Cap431.52M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+230.4% upside
Current
$3.78
$3.78
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $948.45 | -2.72% | 36.1 | 913.24B |
| JNJ | Johnson & Johnson | $221.32 | -0.53% | 26.1 | 548.94B |
| MRK | Merck & Co. Inc. | $111.38 | -0.82% | 31.3 | 279.42B |
| PFE | Pfizer Inc. | $25.68 | -3.02% | 19.3 | 150.09B |
| BMY | Bristol-Myers Squibb Co | $56.16 | -0.16% | 17.0 | 120.08B |
| ZTS | Zoetis Inc | $82.83 | -5.13% | 21.5 | 57.37B |